| 0.6 -0.1 (-14.27%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.74 | 1-year : | 4.1 |
| Resists | First : | 2.35 | Second : | 3.51 |
| Pivot price | 1.82 |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 1.97 |
| MA(100) : | 3.79 |
MA(250) : | 7.45 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 7  |
D(3) : | 6.7 |
| RSI | RSI(14): 21.6 | |||
| 52-week | High : | 22.15 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASLN ] has closed above bottom band by 6.8%. Bollinger Bands are 13.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.6 - 0.61 | 0.61 - 0.61 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.59 - 0.6 | 0.6 - 0.61 |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Wed, 17 Jul 2024
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Wed, 17 Jul 2024
Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40% - Benzinga
Mon, 15 Jul 2024
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - StockTitan
Mon, 15 Jul 2024
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - GlobeNewswire
Mon, 15 Jul 2024
ASLAN Pharmaceuticals faces delisting from Nasdaq - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 410 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 13.2 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 37 (K) |
| EPS | -16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -7.7 |
| Profit Margin | -291.9 % |
| Operating Margin | -291.1 % |
| Return on Assets (ttm) | -53.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.24 |
| EBITDA (p.s.) | -12.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.08 |
| Price to Sales | 0.14 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|